WHITNEY NORMAN: Open Payments
NPI 1992561328 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,502 in 91 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $731 · 2025 $2,502
Food & beverage: $2,494Education: $8
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $594 |
| Otsuka America Pharmaceutical, Inc. | 16 | $433 |
| Janssen Pharmaceuticals, Inc | 13 | $339 |
| Teva Pharmaceuticals USA, Inc. | 11 | $246 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $219 |
| Alkermes, Inc. | 9 | $170 |
| Supernus Pharmaceuticals, Inc. | 1 | $127 |
| Lundbeck LLC | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Axsome Therapeutics, Inc. | 3 | $71 |
Products named: COBENFY, REXULTI, INVEGA SUSTENNA, CAPLYTA, UZEDY, ABILIFY ASIMTUFII, ARISTADA, Qelbree.
Industry payments across MO — which companies pay providers there.
